CCRM Nordic and Precision BioAnalytics forge venture partnership to accelerate ATMP development
..............................................................
GU Ventures share news and information about the business, its companies, and alumni companies:
..............................................................
CCRM Nordic, a leading organization dedicated to advancing research, development and commercialization of advanced therapy medicinal products (ATMPs), today announced its first strategic venture investment, becoming a shareholder in Precision BioAnalytics AB, a pioneer in advanced molecular analysis services.
The venture partnership formalises a collaboration already underway and reinforces both organisations’ commitment to advancing ATMP development across the Nordics and globally.
By investing in Precision BioAnalytics, CCRM Nordic is further expanding its offering beyond current analytical services. The result is a unique combined offering of infrastructure, scientific expertise and precision analytics that supports biotech, pharma and academic innovators from concept to commercialization.
“At CCRM Nordic, we are building a next-generation innovation hub to enable smarter, faster and more effective development of advanced therapies and analytics,” said Fredrik Wessberg, CEO of CCRM Nordic. “Partnering with Precision BioAnalytics − and now investing in their future – is not just a service expansion. This is a statement of intent to co-create impact with some of the most exciting science in Europe.”
Precision BioAnalytics brings more than three decades of leadership in molecular analysis, offering proprietary methods and validated technologies that enable exceptional measuring sensitivity and precision. With a track record of over 300 publications and contributions to key global standards (MIQE, ISO, AAPS white papers), Precision BioAnalytics is uniquely positioned to deliver actionable insights from even the most complex biological samples.
“We are super excited to deepen our partnership with CCRM Nordic,” said Professor Mikael Kubista, co-founder of Precision BioAnalytics. “Their translational vision and infrastructure, combined with our analytical precision, creates a powerful platform for developing tomorrow’s healthcare solutions.”
The partnership strengthens support for drug development and clinical trials, offering bespoke assays, streamlined workflows and advanced sample analysis. Already active in oncology, respiratory disease and immunology, the venture also paves the way for breakthroughs in AI-driven diagnostics, biomarker validation and cell and gene therapies.
Media contact:
Fredrik Wessberg
CEO, CCRM Nordic
fredrik.wessberg@ccrmnordic.se
+46 722 296905
About CCRM Nordic
CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs. Learn more about CCRM Nordic: ccrmnordic.se/
About Precision BioAnalytics
Precision BioAnalytics is Europe’s leading provider of advanced molecular analysis services. The founders of Precision BioAnalytics bring over 30 years of expertise in molecular diagnostics. They co-authored the MIQE and dMIQE guidelines, which serve as global standards for designing and reporting qPCR and dPCR studies. They were also instrumental in the SPIDIA consortium, contributing to 23 CEN technical specifications and ISO guidelines that shape preanalytical processes in the diagnostic field. Most recently, they co-authored white papers for the American Association of Pharmaceutical Scientists (AAPS) on the applications of qPCR and dPCR in cell and gene therapy development. Precision BioAnalytics pushes the boundaries of molecular analysis with proprietary technologies that deliver unmatched sensitivity and precision. Learn more about Precision BioAnalytics: precisionbioanalytics.com/